Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 dose-escalation study of DS1025a in advanced solid tumors
jRCT2031260320Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS1025a in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of participants reporting dose-limiting toxicities, Number of participants reporting adverse events and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
DS1025a
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260320.